^
BIOMARKER:

PIK3CG expression

i
Other names: PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma, Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma Isoform, Serine/Threonine Protein Kinase PIK3CG, PtdIns-3-Kinase Subunit P110-Gamma, PtdIns-3-Kinase Subunit Gamma, PI3-Kinase Subunit Gamma, PI3Kgamma, P110gamma, P120-PI3K, Phosphatidylinositol-4 5-Bisphosphate 3-Kinase 110 KDa Catalytic Subunit Gamma, Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Gamma Isoform, Phosphatidylin
Entrez ID:
Related biomarkers:
14d
NR0B2 is a prognosis factor for patient survival in liver cancers. MAPK and PI3K oppositely modulate NR0B2 expression, and NR0B2 gene upregulation might serve as a therapeutic responsiveness factor in anti-PI3K therapy for liver cancer.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
PIK3CG expression • PIK3CA expression
6ms
Immunohistochemistry in human prostate cancer specimens found that expression of PIK3CG is significantly associated with advanced clinical stages. Taken together, these results suggest that Pik3cg plays an important role in the progression and metastasis of prostate cancer, and may represent a new therapeutic target in the metastatic castration-resistant prostate cancer.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • AR (Androgen receptor) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
PIK3CG expression • AR expression
9ms
The present study revealed distinct antitumor effects against PC cell lines by PI3K/AKT or CDK pathway intervention. Sequencing data revealed genetic background changes in PC cell lines. These results provide data necessary for studies in exploring relationship between altered genetic background and inhibitor Response.
Preclinical
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
PIK3CA mutation • PIK3CG expression
|
MK-2206 • buparlisib (BKM120) • dinaciclib (PS-095760) • silmitasertib (CX-4945)
9ms
The present study revealed distinct antitumor effects against PC cell lines by PI3K/AKT or CDK pathway intervention. Sequencing data revealed genetic background changes in PC cell lines. These results provide data necessary for studies in exploring relationship between altered genetic background and inhibitor Response.
Preclinical
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
PIK3CA mutation • PIK3CG expression
|
MK-2206 • buparlisib (BKM120) • dinaciclib (PS-095760) • silmitasertib (CX-4945)
9ms
The present study revealed distinct antitumor effects against PC cell lines by PI3K/AKT or CDK pathway intervention. Sequencing data revealed genetic background changes in PC cell lines. These results provide data necessary for studies in exploring relationship between altered genetic background and inhibitor Response.
Preclinical
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
PIK3CA mutation • PIK3CG expression
|
MK-2206 • buparlisib (BKM120) • dinaciclib (PS-095760) • silmitasertib (CX-4945)
1year
These results indicate that PI3Kδ expression is observed in both the immune cells which are fashioning the suppressive microenvironment and in cancer cells. These findings suggest an approach to identify patients for treatment guided by cell type expression of PI3K isoforms, and provide strategies for duvelisib use as monotherapy and in combinations with PD-1 checkpoint inhibitors and other agents.
BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CD8 (cluster of differentiation 8) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • BRCA (Breast cancer early onset)
|
PIK3CD expression • PIK3CG expression
|
Copiktra (duvelisib)
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our